LALPATHLAB Dr. Lal Path Labs Q2 FY26 results (Jul–Sep 2025) and concall
Dr Lal Pathlabs delivered a resilient Q2 FY26 performance characterized by double-digit revenue growth and margin expansion despite a lower incidence of seasonal illnesses like Dengue and Malaria. Management demonstrated high confidence in the business model by announcing a 1:1 bonus issue and maintaining full-year growth guidance. The company is successfully pivoting toward higher-complexity testing and expanding its radiology pilot while maintaining a strong focus on the B2C segment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 10.8%, net profit up 16.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 +11% |
| EBITDA | 202 | 154 | 169 | 192 | 224 +11% |
| Net profit | 131 | 98 | 156 | 134 | 152 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
